Loading
ASP2138 is an experimental bispecific antibody from Astellas Pharma Global Development in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2 and CD3.
ASP2138 is a bispecific antibody developed by Astellas Pharma Global Development. Its targets are Claudin 18.2 and CD3 (the sponsor names CLDN18.2 x CD3). The sponsor states: Binds CLDN18.2 (claudin 18.2) on tumour cells and CD3 on T cells, bringing T cells into proximity with CLDN18.2-expressing tumour cells to activate an anti-tumour T-cell response; administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673887 (A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer), in gastric & gastro-oesophageal junction cancer. The largest, NCT07673887, plans to enrol 570 participants with primary completion expected 2031-02-28. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Binds CLDN18.2 (claudin 18.2) on tumour cells and CD3 on T cells, bringing T cells into proximity with CLDN18.2-expressing tumour cells to activate an anti-tumour T-cell response; administered subcutaneously. Connects to Claudin 18.2 and CD3.
1.One arm of ASP2138 binds Claudin 18.2 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ASP2138" OR ABSTRACT:"ASP2138") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ASP2138, not a curated reading list.
Shares Claudin 18.2-positive gastric cancer, Astellas, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, CD3, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Astellas, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.